the role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer表皮生长因子受体突变的作用,表皮生长因子受体酪氨酸激酶抑制剂治疗肺癌.pdfVIP

the role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer表皮生长因子受体突变的作用,表皮生长因子受体酪氨酸激酶抑制剂治疗肺癌.pdf

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
the role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer表皮生长因子受体突变的作用,表皮生长因子受体酪氨酸激酶抑制剂治疗肺癌

Cancers 2011, 3, 2667-2678; doi:10.3390/cancers3022667 OPEN ACCESS cancers ISSN 2072-6694 /journal/cancers Review The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer Shih-Chieh Chang 1, Cheng-Yu Chang 2 and Jin-Yuan Shih 3,* 1 Department of Internal Medicine, National Yang-Ming University Hospital, Yilan 260, Taiwan; E-Mail: dtsurga9@.tw (S.-C.C.) 2 Department of Chest Medicine, Far Eastern Memorial Hospital, Taipei 220, Taiwan; E-Mail: koala2716@ (C.-Y.-C.) 3 Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei 100, Taiwan * Author to whom correspondence should be addressed: E-Mail: jyshih@.tw; Tel: +886-2 Fax: +886-2 Received: 28 April 2011; in revised form: 1 June 2011 / Accepted: 7 June 2011 / Published: 10 June 2011 Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) cases comprise approximately 85% of the lung cancer cases. Before the era of target therapy, platinum-based doublet chemotherapy only led to a median survival of 8–9 months and a one-year survival of 30%–40% in patients with advanced NSCLC. In July 2002, gefitinib, a small-molecule epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), was approved for the treatment of patients with advanced NSCLC in Japan. After the widespread use of gefitinib in the treatment of

您可能关注的文档

文档评论(0)

118zhuanqian + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档